Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive degeneration of motoneurons, which is preceded by loss of neuromuscular connections in a "dying back" process. Neuregulin-1 (Nrg1) is a neurotrophic factor essential for the development and maintenance of neuromuscular junctions, and Nrg1 receptor ErbB4 loss-of-function mutations have been reported as causative for ALS. Our main goal was to investigate the role of Nrg1 type I (Nrg1-I) in SOD1 G93A mice muscles. We overexpressed Nrg1-I by means of an adeno-associated viral (AAV) vector, and investigated its effect by means of neurophysiological techniques assessing neuromuscular function, as well as molecular approaches (RT-PCR, western blot, immunohistochemistry, ELISA) to determine the mechanisms underlying Nrg1-I action. AAV-Nrg1-I intramuscular administration promoted motor axon collateral sprouting by acting on terminal Schwann cells, preventing denervation of the injected muscles through Akt and ERK1/2 pathways. We further used a model of muscle partial denervation by transecting the L4 spinal nerve. AAV-Nrg1-I intramuscular injection enhanced muscle reinnervation by collateral sprouting, whereas administration of lapatinib (ErbB receptor inhibitor) completely blocked it. We demonstrated that Nrg1-I plays a crucial role in the collateral reinnervation process, opening a new window for developing novel ALS therapies for functional recovery rather than preservation.
Introduction
ALS is a progressive degenerative disease selectively affecting motoneurons (Kiernan et al., 2011) . Approximately 10% of patients have familial forms, caused by mutations in a variety of genes, the most prevalent involving the superoxide dismutase 1 (sod1) gene and hexanucleotide repeat expansions in chromosome-9 open reading frame 72 (C9ORF72) (Andersen and Al-Chalabi, 2011; Turner et al., 2013) . Although C9ORF72 gene mutations are reported in a higher proportion of ALS and ALS-frontotemporal lobar degeneration patients (DeJesus-Hernandez et al., 2011; Renton et al., 2011) , SOD1-based models are still the most used tool for basic and preclinical studies. The most widely used ALS model is a transgenic mouse over-expressing the human mutated form of the SOD1 gene with a glycine to alanine conversion at the 93rd amino acid (Gurney et al., 1994; Ripps et al., 1995) , which recapitulates the most relevant clinical and histopathological features of both familial and sporadic ALS (Ripps et al., 1995; Mancuso et al., 2011a Mancuso et al., , 2011b . High copy SOD1 G93A transgenic mice develop rapidly progressive motoneuron loss, with locomotor deficits from 12 to 13 weeks of age, hindlimb weakness and muscle atrophy, culminating in paralysis and death between ages 16 and 19 weeks (Ripps et al., 1995; Mancuso et al., 2011a Mancuso et al., , 2011b . Alterations in SOD1 protein have also been found in sporadic ALS patients (Bosco et al., 2010) , and accumulation of wildtype SOD1 was reported to produce ALS in mice (Graffmo et al., 2013) .
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